Metastasis, the dissemination and growth of neoplastic cells in an organ distinct from that in which they originated 1,2 , is the most common cause of death in cancer patients. This is particularly true for pancreatic cancers, where most patients are diagnosed with metastatic disease and few show a sustained response to chemotherapy or radiation therapy 3 . Whether the dismal prognosis of patients with pancreatic cancer compared to patients with other types of cancer is a result of late diagnosis or early dissemination of disease to distant organs is not known. Here we rely on data generated by sequencing the genomes of seven pancreatic cancer metastases to evaluate the clonal relationships among primary and metastatic cancers. We find that clonal populations that give rise to distant metastases are represented within the primary carcinoma, but these clones are genetically evolved from the original parental, non-metastatic clone. Thus, genetic heterogeneity of metastases reflects that within the primary carcinoma. A quantitative analysis of the timing of the genetic evolution of pancreatic cancer was performed, indicating at least a decade between the occurrence of the initiating mutation and the birth of the parental, non-metastatic founder cell. At least five more years are required for the acquisition of metastatic ability and patients die an average of two years thereafter. These data provide novel insights into the genetic features underlying pancreatic cancer progression and define a broad time window of opportunity for early detection to prevent deaths from metastatic disease.
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We performed rapid autopsies of seven individuals with end stage pancreatic cancer ( Supplementary Table 1 ). In all patients, metastatic deposits were present within two or more anatomic sites in each patient, most often the liver, lung and peritoneum, as is typical for this form of neoplasia 4 .
Low passage cell lines (six patients) or first passage xenografts (one patient) were created from one of the metastases present at each patient's autopsy. These samples comprised seven of the 24 pancreatic cancers which previously underwent whole exome sequencing and copy number analysis, as described in a mutational survey of the pancreatic cancer genome 5 . In this earlier study, a total of 426 somatic mutations in 388 different genes were identified among 220,884,033 base pairs (bp) sequenced in the seven index metastatic lesions, corresponding to an average of 61 mutations per index metastatic lesion (range 41-77). In all samples, the vast majority of mutations were represented by missense or silent single base substitutions (Supplementary Fig. 1 and Supplementary Table 2 ).
For each of the somatic mutations identified in the seven index metastasis lesions, we determined whether the same somatic mutation was present in anatomically distinct metastases harvested at autopsy from the same patients. We also determined whether these mutations were present in the primary pancreatic tumours from which the metastases arose. A small number of these samples of interest were cell lines or xenografts, similar to the index lesions, whereas the majority were fresh-frozen tissues that contained admixed neoplastic, stromal, inflammatory, endothelial and normal epithelial cells ( Fig. 1a ). Each tissue sample was therefore microdissected to minimize contaminating non-neoplastic elements before purifying DNA.
Two categories of mutations were identified (Fig. 1b ). The first and largest category corresponded to those mutations present in all samples from a given patient ('founder' mutations, mean of 64%, range 48-83% of all mutations per patient; Fig. 1b , example in Supplementary Fig. 2a ). These data indicate that the majority of somatically acquired mutations present in pancreatic cancers occur before the development of metastatic lesions. All other mutations were characterized as 'progressor' mutations (mean of 36%, range 17-52% of all mutations per patient; Supplementary Fig. 2b ). These mutations were present in one or more of the metastases examined, including the index metastasis, but not the parental clone. These mutation types were used to classify the lesions that contained them into parental clones (containing only founder mutations) and subclones (containing both founder and progressor mutations). By definition, there could be only one parental clone in a patient, although there could be many different subclones. Parental clones tended to contain more deleterious mutations (nonsense, splice site or frameshift mutations) than subclones (12.6% of the mutations in the parental clones versus 8.1% of the mutations in subclones, Supplementary Table 2 ). The parental clones had already accumulated mutations in all driver genes (KRAS, TP53 and SMAD4) previously shown to drive pancreatic tumorigenesis 6 . Through combined analysis of high-density single nucleotide polymorphism (SNP) chip data on the index lesion ( Supplementary Table 3 ) plus the sequencing data on all lesions (Supplementary Table 2 ) we found that the vast majority of homozygous mutations (51 mutations, representing 89% of all homozygous mutations) in the index lesion were already present in the parental clones. Homozygous mutations are characteristic of tumour suppressor genes such as SMAD4 and CDKN2A and often occur in association with chromosomal instability 7 . In sum, the parental clones harboured the majority of deleterious genetic alterations and chromosomal instability, upon which were superimposed an accumulation of progressor mutations associated with clonal evolution and metastasis.
Evolutionary maps were constructed for each patient's carcinoma based on the patterns of somatic mutation and allelic losses and the locations of individual metastatic deposits ( Fig. 2 and Supplementary  Figs 3-8 ). These maps showed that, despite the presence of numerous founder mutations within the parental clones, the cells giving rise to the metastatic lesions had a large number of progressor mutations. For example, in Pa01 the parental clone contained 49 founder mutations, yet a clonal expansion marked by the presence of mutations in six additional genes was present in the lung and peritoneal metastases ( Supplementary Fig. 3 ). Moreover, 22 more mutations were found in the liver metastasis. Note that all mutations in the metastatic lesions were clonal, that is, present in the great majority if not all neoplastic cells of the metastasis, as assessed by Sanger sequencing. Thus, these mutations were present in the cell that clonally expanded to become the metastasis. Similarly, large numbers of progressor mutations were generally observed in the metastases from each of the seven cases examined ( Fig. 2 and Supplementary Figs 3-8 ).
To distinguish between the possibilities that clonal evolution occurred inside the primary cancer versus within secondary sites, we sectioned the primary tumours from two patients into numerous, threedimensionally organized pieces ( Fig. 2a, b ) and examined the DNA 
Liver Liver e f c Figure 2 | Geographic mapping of metastatic clones within the primary carcinoma and proposed clonal evolution of Pa08. a, Illustration of the pancreatic specimen removed from Pa08 at rapid autopsy, and the planes of sectioning of the specimen. b, Mapping of the parental clone and subclones identified by comparative lesion sequencing within serial sections of the infiltrating pancreatic carcinoma. Metastatic subclones giving rise to liver and lung metastases are non-randomly located within slice 3, indicated by blue circles. These clones are both geographically and genetically distinct from clones giving rise to peritoneal metastases in this same patient, indicated in green. c, Proposed clonal evolution based on the sequencing data. In this model, after development of the parental clone, ongoing clonal evolution continues within the primary carcinoma (yellow rectangle), and these subclones seed metastases in distant sites. *Two mutations were found in the TTN gene.
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from each piece for each of the founder and progressor mutations. In Patient Pa08, there were three progressor mutations present in two independent peritoneal metastases (defining one subclone) and 23, 25 or 27 additional progressor mutations present in liver and lung metastases (defining three additional subclones; Fig. 2c ). Through the analysis of distinct regions of the primary tumour, it was clear that subclones giving rise to each of these metastases were present in the primary tumour. Moreover, these subclones were not small; from the size of the pieces (Fig. 2a ) and the amounts of DNA recovered, each subclone must have contained in excess of 100 million cells. In addition, more than four different subclones, each containing a similarly large number of cells, could be identified through the analysis of other pieces of the same tumour. These subclones could be put into an ordered hierarchy establishing an evolutionary path for tumour progression (Fig. 2c) . Analysis of multiple primary tumour pieces and metastatic lesions from patient Pa04 revealed a similar clonal evolution, with distinct, large subclones within the primary tumours giving rise to the various metastases ( Supplementary Fig. 8 ).
To clarify further clonal evolution within the primary site, we attempted to correlate the mutation signatures representing the subclones of Pa08 (Fig. 2c) with the geographic location of the pieces of the primary tumour used to define them ( Fig. 2a, b ). Samples representative of the parental clone were located throughout the primary carcinoma. By contrast, samples representing subclones were non-randomly located in proximity to each other, within which the subclones specifically giving rise to peritoneal versus distant metastases were seen. Thus, we conclude that the genetic heterogeneity of metastases reflects heterogeneity already existing within the primary carcinoma, and that the primary carcinoma is a mixture of numerous subclones, each of which has independently expanded to constitute a large number of cells.
This data set could also be used to infer the timing of the development of the various stages of pancreatic tumour progression 8 . We assume that the tumour is initiated by a genetic event that confers a selective growth advantage to the cell that goes on to become the founder cell of the tumour. To estimate the timing, we first used Ki-67 labelling to determine the proliferation rate of seven samples of normal duct epithelium from surgically resected pancreata of individuals without pancreatic cancer as well as of each index metastasis. Ki-67-positive nuclei constituted an average of 0.4% of normal ductal cells, whereas an average of 16.3% of cancer cells within the index metastasis lesions were Ki-67-positive, consistent with prior estimates 9,10 ( Supplementary Table 4 ). Based on these data plus that from sequencing of the index lesions, we derived estimates for three critical times in tumour evolution: T 1 , the time between tumour initiation and the birth of the cell giving rise to the parental clone; T 2 , the subsequent time required for the birth of the cell that gave rise to the index metastasis; and T 3 , the time between the dissemination of this cell and the patients' death ( Fig. 3) . In other words, there is a time point, t 0 , when the tumour was initiated, and a time point t 1 when a cell is born that has all mutations that exist in the parental clone. Similarly, there is a time point in tumour evolution, t 2 , when a cell is born that has all the mutations that exist in the index metastasis. T 1 is given by t 1 2 t 0 and T 2 is given by t 2 2 t 1 . If we denote t 3 as the time of patient's death, then T 3 5 t 3 2 t 2 . Using the mathematical model described in the Methods, we were able to conservatively estimate an average of 11.7 years from the initiation of tumorigenesis until the birth of the cell giving rise to the parental clone, an average of 6.8 years from then until the birth of the cell giving rise to the index lesion, and an average of 2.7 years from then until the patients' death (see Supplementary Discussion and Supplementary Table 5 ).
We show, for the first time, that primary pancreatic cancers contain a mix of geographically distinct subclones, each containing large numbers (hundreds of millions) of cells that are present within the primary tumour years before the metastases become clinically evident. The features of these metastatic subclones that promote metastasis formation have yet to be discerned, because no consistent genetic signature of metastatic subclones could be identified. We did identify several genes Tumorigenesis begins with an initiating mutation in a normal cell that confers a selective growth advantage. Successive waves of clonal expansion occur in association with the acquisition of additional mutations, corresponding to the progression model of pancreatic intraepithelial neoplasia (PanIN) and time T 1 . One founder cell within a PanIN lesion will seed the parental clone and hence initiate an infiltrating carcinoma (end of T 1 and beginning of T 2 ). Eventually, the cell that will give rise to the index lesion will appear (end of T 2 and beginning of T 3 ). Unfortunately, most patients are not diagnosed until well into time interval T 3 when cells of these metastatic subclones have already escaped the pancreas and started to grow within distant organs. The average time for intervals T 1, T 2 and T 3 for all seven patients is indicated in the parentheses at left (see also Supplementary Table 6 ).
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that were mutated in one or more of the index metastatic lesions from these seven patients with Stage IV disease, but not in the primary pancreatic index lesions from 17 patients with Stage II disease (Supplementary Table 2 ). These genes include those that may have a role in invasive or metastatic ability through heterotypic cell adhesion (CNTN5), motility (DOCK2), proteolysis (MEP1A) and tyrosine phosphorylation (LMTK2). However, these mutations were not metastasisspecific per se as all but one were present in the matched primary carcinoma of those same seven patients, and there is no evidence that the mutations we observed endowed these genes with metastagenic activity. These data also do not reveal the selective pressures within the primary carcinoma that led to the formation of progressor mutations. In light of recent findings indicating that pancreatic cancers are poorly vascularized 11 , one possibility is that intratumoural hypoxia creates a fertile microenvironment for the formation of additional mutations beyond that of the parental clone.
One of the major implications of these data is their implication for screening to prevent pancreatic cancer deaths. Quantitative analysis indicated a large window of opportunity for diagnosis while the disease was still in the curative stage-at least a decade. Our model also predicts an average of 6.8 years between the birth of the cell giving rise to the parental clone and the seeding of the index metastasis. Unfortunately, the great majority of patients are not diagnosed until the last 2 years of the entire tumorigenic process. The challenge is to detect these tumours during time T 1 , or even after T 1 but before seeding of metastases. Advanced imaging methods, as well as blood tests to detect cancerspecific proteins, transcripts or genes 12 , offer hope for such non-invasive early detection.
METHODS SUMMARY
Rapid autopsies were performed on seven individuals with Stage IV pancreatic cancer 13 . Genomic DNA was extracted from cell lines or xenografts established from one metastasis of each patient and used for exomic sequencing as described previously 5 . The Illumina Infinium II Whole Genome Genotyping Assay using the BeadChip platform was also used to analyse each sample at 1,072,820 (1M) SNP loci as described previously 5 . Samples of snap-frozen pancreatic cancer tissue were microdissected using a PALM MicroLaser System (Carl Zeiss MicroImaging) and DNA extracted using QIAamp DNA Micro Kits (Qiagen). Genomic DNA was quantified by calculating long interspersed nuclear elements (LINE) by real-time PCR. Whole genome amplification (WGA) was performed using 10 ng total template DNA and an illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare). Ki-67 immunolabelling (Clone MIB-1, Dako Cytomation) was performed on formalin-fixed, paraffin-embedded sections of normal pancreatic ducts and metastatic pancreatic cancer tissues for each patient using the Ventana Discovery staining system (Ventana Medical Systems), and this information was used to inform computational models of the timing of clonal evolution of each patient's pancreatic cancer (full details of these models are available in Full Methods).
